Ipamorelin: Identity, Research Evidence, and Regulatory Status

Last evidence review: August 27, 2026

Ipamorelin is a synthetic five-residue growth-hormone secretagogue. Its sequence includes non-proteinogenic amino acids, and FDA treats the free base and acetate as distinct bulk drug substances.[1]

Ipamorelin is often discussed beside GHRH analogs such as CJC-1295, but it belongs to a different mechanistic class. The primary literature characterizes it within the growth-hormone-secretagogue or ghrelin-receptor system.

Experimental studies have measured receptor-linked signaling, pituitary growth-hormone release, and gastrointestinal-motility endpoints. A controlled human study reported a short-term hormone response, but a randomized phase 2 postoperative-ileus study did not show statistically significant benefit on its key or secondary efficacy measures.[2][5]

A hormone response should not be presented as proof of improved body composition, recovery, sleep, athletic performance, or health.

Identity at a glance

A product name alone does not establish free base versus acetate or the exact material used in a paper.

Laboratory evidence

The foundational pharmacology study tested ipamorelin in primary rat pituitary cells and used antagonist experiments to characterize a growth-hormone-secretagogue-receptor-like mechanism.[2] The investigators reported hormone release in the cell system and compared the response with other secretagogues.

This is an experimental signaling and secretion observation. It does not demonstrate clinical benefit or establish the consequences of chronic exposure in people.

Animal evidence

The same study reported hormone responses in rats and swine.[2] Under the tested conditions, ipamorelin produced less ACTH and cortisol response than comparator secretagogues. That does not establish endocrine selectivity or safety in every species, exposure pattern, or human population.

Separate rat studies examined gastrointestinal transit and gastric emptying after experimental abdominal surgery.[3][4] Some model endpoints differed from vehicle controls. Those findings supported human investigation of postoperative ileus, but the later human trial did not meet its efficacy endpoints.

What human evidence exists?

Healthy-volunteer pharmacology study

A controlled pharmacokinetic and pharmacodynamic study in healthy male volunteers measured short-term hormone responses across several study groups.[5] It reported approximately proportional exposure and an episodic growth-hormone response.

The study did not evaluate a patient-centered outcome and cannot establish treatment effectiveness.

Randomized phase 2 postoperative-ileus study

A multicenter, randomized, double-blind, placebo-controlled phase 2 study enrolled 117 bowel-resection patients, with 114 included in the safety and modified intention-to-treat populations. The studied intervention did not produce statistically significant differences from placebo in the key endpoint or secondary efficacy analyses.[6]

FDA’s later review discussed adverse events observed in that program, including two deaths, while explicitly stating that it was unclear whether the deaths were related to ipamorelin.[1] That causality limitation must remain visible.

Why the intravenous study does not establish subcutaneous pharmacokinetics

The healthy-volunteer pharmacokinetic study characterized ipamorelin administered by intravenous infusion and modeled its accompanying growth-hormone response. Those concentration-time findings describe the route and conditions actually studied; they do not establish how much of a subcutaneous preparation would reach circulation or how quickly it would be absorbed.

In its October 2024 evaluation, FDA specifically reported that it had not identified pharmacokinetic or pharmacodynamic information for subcutaneous ipamorelin free base or acetate. FDA also noted that the form used in the intravenous report was unspecified. Consequently, that paper cannot support a route-independent half-life claim or demonstrate comparability between a separately sourced material and the investigational preparation. A transient hormone response also remains a pharmacology observation, rather than evidence of a patient-centered clinical benefit.

What the evidence does not establish

• It does not establish improved muscle mass, fat loss, recovery, sleep, skin, cognition, libido, athletic performance, or anti-aging effects.
• It does not establish clinical effectiveness for growth-hormone deficiency or postoperative ileus.
• It does not establish safety for routes or exposure patterns not studied.
• It does not characterize long-term endocrine, metabolic, reproductive, cardiovascular, immunogenic, or carcinogenic risk.
• It does not establish that ipamorelin and a GHRH analog have synergistic effects or that a blend behaves like either component alone.

Current regulatory status

FDA’s 2024 review states that neither ipamorelin free base nor ipamorelin acetate has an applicable USP or National Formulary drug-substance monograph and neither is a component of an FDA-approved drug. FDA proposed not adding either form to the section 503A Bulks List.[1]

FDA’s current compounding safety page lists ipamorelin acetate in Category 2 under the section 503B interim policy and cites characterization and potential immunogenicity concerns.[7]

These compounding classifications are not FDA drug approvals and should be checked on every review date.

Frequently asked questions

Is ipamorelin a GHRH analog?

No. Ipamorelin is characterized as a growth-hormone secretagogue within the ghrelin-receptor system. CJC-1295 is a GHRH analog. They are not the same compound or mechanistic class.

What did the human studies show?

A healthy-volunteer study measured pharmacokinetics and a short-term hormone response. A later randomized phase 2 postoperative-ileus study did not find statistically significant improvement in its key or secondary efficacy outcomes.

Is ipamorelin FDA approved?

FDA states that ipamorelin free base and acetate are not components of an FDA-approved drug.

Primary and official sources

1. FDA October 2024 ipamorelin briefing document
2. Foundational pharmacology, PMID 9849822
3. Rat postoperative-ileus model, PMID 19289567
4. Rat gastric-dysmotility model, PMID 27186127
5. Healthy-volunteer PK/PD study, PMID 10496658
6. Randomized phase 2 study, PMID 25331030
7. FDA substances that may present significant compounding safety risks